{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:08:49Z","timestamp":1792058929632,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-42989-9","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T10:14:01Z","timestamp":1772964841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ibuzatrelvir potently reduced viral RNA levels despite a high rate of anti-S seropositivity: a post hoc analysis of serology of the phase 2b study"],"prefix":"10.1038","volume":"16","author":[{"given":"Jin Hyang","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Knutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunjie","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke F.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahta","family":"Mortezavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lynn","family":"Baniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Allerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar Niki","family":"Alami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"issue":"6","key":"42989_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","volume":"21","author":"PV Markov","year":"2023","unstructured":"Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21(6), 361\u2013379 (2023).","journal-title":"Nat. Rev. Microbiol."},{"issue":"8","key":"42989_CR2","doi-asserted-by":"publisher","first-page":"e632","DOI":"10.1016\/S2666-5247(23)00139-8","volume":"4","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. Viral and antibody dynamics of acute infection with SARS-CoV-2 Omicron variant (B.1.1.529): A prospective cohort study from Shenzhen, China. Lancet Microbe 4(8), e632\u2013e641 (2023).","journal-title":"Lancet Microbe"},{"key":"42989_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n3151","volume":"375","author":"E Mahase","year":"2021","unstructured":"Mahase, E. COVID-19: Hospital admission 50\u201370% less likely with Omicron than Delta, but transmission a major concern. BMJ 375, n3151 (2021).","journal-title":"BMJ"},{"key":"42989_CR4","doi-asserted-by":"crossref","unstructured":"Jones JM, M.I., Stone MS, et al. , Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status \u2014 United States, April 2021\u2013September 2022. MMWR Morb Mortal Wkly Rep, 2023. 72: p. 601\u2013605.","DOI":"10.15585\/mmwr.mm7222a3"},{"issue":"1","key":"42989_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36984-1","volume":"14","author":"U Marking","year":"2023","unstructured":"Marking, U. et al. Correlates of protection and viral load trajectories in Omicron breakthrough infections in triple vaccinated healthcare workers. Nat. Commun. 14(1), 1577 (2023).","journal-title":"Nat. Commun."},{"issue":"2","key":"42989_CR6","doi-asserted-by":"publisher","first-page":"e02980","DOI":"10.1128\/spectrum.02980-23","volume":"12","author":"K Borroto-Esoda","year":"2024","unstructured":"Borroto-Esoda, K. et al. SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir. Microbiol. Spectr. 12(2), e02980-e3023 (2024).","journal-title":"Microbiol. Spectr."},{"key":"42989_CR7","unstructured":"Viera, M.a.I.C.J. Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19. 2023; Available from: https:\/\/www.businesswire.com\/news\/home\/20230508005600\/en\/."},{"key":"42989_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae529","author":"M Mortezavi","year":"2024","unstructured":"Mortezavi, M. et al. Virologic response and safety of Ibuzatrelvir, a novel SARS-CoV-2 antiviral, in adults with COVID-19. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciae529 (2024).","journal-title":"Clin. Infect. Dis."},{"issue":"64","key":"42989_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl4509","volume":"6","author":"B Israelow","year":"2021","unstructured":"Israelow, B. et al. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci. Immunol. 6(64), eabl4509 (2021).","journal-title":"Sci. Immunol."},{"issue":"1","key":"42989_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41392-024-01849-6","volume":"9","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies. Signal Transduct. Target. Ther. 9(1), 123 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"42989_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46025-y","volume":"13","author":"N Patel","year":"2023","unstructured":"Patel, N. et al. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants. Sci. Rep. 13(1), 19176 (2023).","journal-title":"Sci. Rep."},{"issue":"3","key":"42989_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chom.2024.01.014","volume":"32","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe 32(3), 315-321.e3 (2024).","journal-title":"Cell Host Microbe"},{"issue":"4","key":"42989_CR13","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40121-022-00648-2","volume":"11","author":"NI Napuri","year":"2022","unstructured":"Napuri, N. I. et al. Immune response to COVID-19 and mRNA vaccination in immunocompromised individuals: A narrative review. Infect. Dis. Ther. 11(4), 1391\u20131414 (2022).","journal-title":"Infect. Dis. Ther."},{"issue":"9","key":"42989_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41577-020-0405-3","volume":"20","author":"N Vabret","year":"2020","unstructured":"Vabret, N. Antibody responses to SARS-CoV-2 short-lived. Nat. Rev. Immunol. 20(9), 519\u2013519 (2020).","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"42989_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22351-5","volume":"12","author":"NA Aziz","year":"2021","unstructured":"Aziz, N. A. et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. Nat. Commun. 12(1), 2117 (2021).","journal-title":"Nat. Commun."},{"issue":"3","key":"42989_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","volume":"57","author":"K Srivastava","year":"2024","unstructured":"Srivastava, K. et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity 57(3), 587-599.e4 (2024).","journal-title":"Immunity"},{"key":"42989_CR17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170681","author":"MD Grant","year":"2023","unstructured":"Grant, M. D. et al. Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.170681 (2023).","journal-title":"JCI Insight"},{"issue":"2","key":"42989_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","volume":"23","author":"P Moss","year":"2022","unstructured":"Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23(2), 186\u2013193 (2022).","journal-title":"Nat. Immunol."},{"key":"42989_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12020118","author":"J Gayed","year":"2024","unstructured":"Gayed, J. et al. Safety and immunogenicity of the monovalent Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine in individuals \u226512 years old: A phase 2\/3 trial. Vaccines https:\/\/doi.org\/10.3390\/vaccines12020118 (2024).","journal-title":"Vaccines"},{"key":"42989_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114387","author":"X-L Jiang","year":"2024","unstructured":"Jiang, X.-L. et al. Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2024.114387 (2024).","journal-title":"Cell Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42989-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42989-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42989-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:33:55Z","timestamp":1776378835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42989-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42989"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42989-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12594"}}